- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06732557
Muscle Energy Technique Versus Mulligan Mobilization on Forward Head Posture
Muscle Energy Technique Versus Mulligan Mobilization on Forward Head Posture: a Randomized Controlled Trial
sixty patients with forward head posture will be randomized to three groups Group A: will receive traditional treatment ( isometric exercise for deep neck flexors plus sub occipital release).
Group B: will receive traditional treatment plus muscle energy technique for upper trapezius, elevator scapulae and sternocleidomastoid.
Group C: will receive traditional treatment plus mulligan mobilization
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Radwa fayek Lecturer at Basic Science Department MTI University, Doctoral
- Phone Number: 02-01004466229
- Email: radwa26fayek@yahoo.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 18 to 45 years
- Non specific neck pain reproduced by neck movement
- Neck pain at least within the last three months
- Limitation in cervical range of motion
Exclusion Criteria:
- cervical spine surgery or injury
- neurologic deficits, infection or inflammation
- cervicogenic headache
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Sham Comparator: Group A: Control group (Traditional treament)
patients will receive traditional treatment (isometric exercise for deep neck flexors plus sub occipital release).
|
Isometric exercise for deep neck flexors and sub occipital release
|
|
Experimental: Group B (muscle energy technique group)
Patients will receive muscle energy Technique for upper trapezius, elevator scapulae and sternocleidomastoid
|
Isometric exercise for deep neck flexors and sub occipital release
Muscle energy technique for upper trapezius, elevator scapulae and sternocleidomastoid
|
|
Active Comparator: Group C (Mulligan Mobilization Group)
Patients will receive Mulligan mobilization
|
Isometric exercise for deep neck flexors and sub occipital release
Mulligan mobilization in the form of SNAGS for rotation, lateral flexion, extension and flexion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain
Time Frame: Before the first session and at the end of the treatment program ( one month)
|
Pain will be measured by visual analogue scale which is a valid and reliable scale for measuring pain starts with zero (represents no pain) and ends with 10 (represents maximum pain).
|
Before the first session and at the end of the treatment program ( one month)
|
|
Cervical range of motion
Time Frame: Before the first session and after the end of the treatment program ( one month)
|
Cervical range of motion in will be measured by cervical range of motion basic assessment device (CROM) the angle of cervical range of motion will be recorded in degrees to determine the limitation in range of motion
|
Before the first session and after the end of the treatment program ( one month)
|
|
Disability measurement
Time Frame: Before the first session and after the end of the treatment program ( one month)
|
Disability will be measured by neck disability index(NDI) is a valid and reliable scale. The NDI consists of ten questions in the following domains: Pain Intensity, Personal Care, Lifting, Reading, Headaches, Concentration, Work, Driving, Sleeping, and Recreation. Scoring: Each question contains six answer choices, scored from 0 (no disability) to 5 (complete disability). All section scores are then totaled. Scoring is reported on a 0-50 scale, 0 being the best possible score and 50 being the worst. Alternately, the score can be reported from 0-100. The score is often reported as a percentage (0-100%). |
Before the first session and after the end of the treatment program ( one month)
|
|
Cervicovertebral angle
Time Frame: Before the first session and after the end of the treatment program ( one month)
|
Cervicovertebral angle (CVA) Will be measure by kinovea: Normal range is between 55 and 86, If the angle is less than 50 degrees, it will be considered to be FHP. Adhesive markers (8 mm in diameter) will be placed on the participant's C7 spinous process and tragus of the ear. The physical therapist will observe the participant from the lateral side while standing and then take a picture of the participant from a fixed distance (75 cm) and height (150 cm), then with the help of an application sealed by a password which is called KINOVEA, the angle will be measured by placing each vector as following a line from the tragus of the ear to the C7 spinous process and another horizontal line through the C7 spinous. The angle will be recorded in degrees |
Before the first session and after the end of the treatment program ( one month)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- P.T.REC/012/005077
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.